

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63

May 3, 2021

ISSUE No.
1623

IN THIS ISSUE

Vibegron (*Gemtesa*) for Overactive Bladder.....p 67

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 63 (Issue 1623)

May 3, 2021

Take CME Exams

▶ Vibegron (*Gemtesa*) for Overactive Bladder

The FDA has approved the selective beta-3 adrenergic agonist vibegron (*Gemtesa* – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is the second beta-3 agonist to be approved in the US; mirabegron (*Myrbetriq*) was the first.¹

Pronunciation Key

Vibegron: vye beg' ron

Gemtesa: jem tes' ah

STANDARD TREATMENT – Overactive bladder (OAB) causes urgency, frequency, nocturia, and incontinence. It occurs most commonly in older women. Management with behavioral modification, including bladder training, urge suppression, pelvic floor muscle exercises, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.

Anticholinergic drugs, such as tolterodine (*Detrol*, and generics) and solifenacin (*Vesicare*, and generics), reduce OAB symptoms by inhibiting involuntary bladder contractions and relaxing detrusor smooth muscle, but they can cause dry mouth and constipation, and their long-term use has been associated with a dose-related increase in the risk of dementia.² Mirabegron appears to be similar in effectiveness to anticholinergic drugs and better tolerated, but it has been associated with small increases in blood pressure.³

Combination therapy with an anticholinergic drug and a beta-3 agonist can be considered when monotherapy is ineffective; mirabegron is FDA-approved for use both alone and in combination with solifenacin. Options for patients with refractory OAB include peripheral tibial nerve stimulation, sacral neuromodulation, and intra-detrusor injection of onabotulinumtoxinA (*Botox*).^{1,4}

Summary: Vibegron (*Gemtesa*)

- ▶ FDA-approved for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency.
- ▶ Second beta-3 agonist to be approved for treatment of overactive bladder; mirabegron (*Myrbetriq*) was the first.
- ▶ Decreased mean daily micturitions compared to placebo and appeared to be similar in efficacy to the anticholinergic drug tolterodine in a double-blind clinical trial.
- ▶ Unlike mirabegron, vibegron has not been associated with blood pressure elevations.
- ▶ Taken once daily with a glass of water; tablets can be swallowed whole or crushed and mixed with applesauce.

MECHANISM OF ACTION – Like mirabegron, vibegron activates beta-3 adrenergic receptors in the bladder, resulting in relaxation of detrusor smooth muscle during the storage phase of the fill-void cycle and increased bladder capacity. Although no direct comparisons are available, vibegron appears to be more selective than mirabegron *in vitro* for beta-3 receptors compared to beta-1 and beta-2 receptors.^{5,6}

Table 1. Pharmacology

Class	Beta-3 adrenergic agonist
Formulation	75 mg tabs
Route	Oral
Tmax (median)	1-3 hours
Metabolism	CYP3A4 (minor)
Elimination	Feces (59%; 54% as unchanged drug); urine (20%)
Half-life (mean)	30.8 hours

CLINICAL STUDIES – FDA approval of vibegron was based on the results of a 12-week, double-blind trial (EMPOWUR) in 1518 patients with symptomatic OAB who were randomized to receive once-daily treatment with vibegron 75 mg, tolterodine extended-release 4 mg (active control), or placebo. At 12 weeks, the reduction in mean daily micturitions, a coprimary endpoint, was significantly greater with vibegron, but not with tolterodine, compared to placebo (-1.8 with

Table 2. Beta-3 Adrenergic Agonists

	Mirabegron (Myrbetriq)	Vibegron (Gemtesa)
Formulations	25, 50 mg ER tabs	75 mg tabs
Usual maintenance dosage	25-50 mg once/day	75 mg once/day
Dosage in hepatic impairment	Child-Pugh B: 25 mg once/day Child-Pugh C: not recommended	Child-Pugh C: not recommended
Dosage in renal impairment	eGFR 15-29 mL/min/ 1.73 m ² : 25 mg once/day eGFR <15 mL/min/ 1.73 m ² : not recommended	eGFR <15 mL/min/ 1.73 m ² : not recommended
Administration	Tablets must be swallowed whole and taken with water	Tablets can be swallowed whole or crushed and mixed with apple- sauce; must be taken with water
CYP interactions	Moderate CYP2D6 inhibitor CYP3A4 and 2D6 substrate (minor)	CYP3A4 substrate (minor)
Effect on blood pressure	Can increase up to 3.5/1.5 mm Hg	No clinically significant effect
Cost ¹	\$417.20	\$458.40

ER = extended-release

1. Approximate WAC for a 30-day supply at the usual maintenance dosage. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly, April 5, 2021. Reprinted with permission by First Databank, Inc. All rights reserved. ©2021. www.fdbhealth.com/policies/drug-pricing-policy.

vibegron, -1.6 with tolterodine, and -1.3 with placebo). The reduction in mean daily urge urinary incontinence episodes, the other coprimary endpoint, was significantly greater with both vibegron and tolterodine than with placebo (-2.0 and -1.8 vs -1.4). Patients taking vibegron also had significant improvements, compared to those taking placebo, in volume voided per micturition, urgency episode frequency, and quality of life.⁷⁻⁹

ADVERSE EFFECTS — The most common adverse effects that occurred more frequently with vibegron than with placebo in EMPOWUR were headache (4.0% vs 2.4%) and nasopharyngitis (2.8% vs 1.7%). The incidence of hypertension was 1.7% in patients taking vibegron, 1.7% in the placebo group, and 2.6% in the tolterodine group. Urinary retention was reported in 0.6% of patients who took vibegron and in 0.4% of those who took placebo.⁷

PREGNANCY AND LACTATION — No data are available on the use of vibegron in pregnant or lactating women. No adverse effects were observed in the offspring of pregnant animals exposed to 89 times the level of

vibegron recommended in humans. Radioactivity has been detected in the milk of lactating rats administered radiolabeled vibegron.

DRUG INTERACTIONS — Taking vibegron with an anticholinergic drug could increase the risk of urinary retention. Concomitant use of vibegron increased the C_{max} and AUC of digoxin by 21% and 11%, respectively.

DOSAGE AND ADMINISTRATION — The recommended dosage of vibegron is 75 mg taken orally once daily with a glass of water. The tablets should either be swallowed whole or crushed and mixed with a tablespoonful of applesauce, and consumed immediately. Vibegron is not recommended for use in patients with end-stage renal disease (eGFR <15 mL/min/1.73 m²) or in those with severe hepatic impairment (Child-Pugh C).

CONCLUSION — The selective beta-3 adrenergic agonist vibegron (*Gemtesa*) was more effective than placebo and appeared to be similar in efficacy to the anticholinergic drug tolterodine for treatment of overactive bladder (OAB) in one 12-week trial. Unlike mirabegron (*Myrbetriq*), the other beta-3 agonist approved for treatment of OAB, vibegron has not been shown to increase blood pressure, but no direct comparisons of the two drugs are available. Behavioral modification is still preferred for initial treatment of OAB, but mirabegron and vibegron, which have few drug interactions and lack anticholinergic adverse effects, are reasonable choices for patients who require pharmacologic treatment. ■

- DJ Lightner et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. *J Urol* 2019; 202:558.
- SL Gray et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med* 2015; 175:401.
- Mirabegron (Myrbetriq) for overactive bladder. *Med Lett Drugs Ther* 2013; 55:13.
- Botox for overactive bladder. *Med Lett Drugs Ther* 2013; 55:31.
- J Di Salvo et al. Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. *J Pharmacol Exp Ther* 2017; 360:346.
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Betmiga. Available at: <https://bit.ly/31TDy1Z>. Accessed April 15, 2021.
- D Staskin et al. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. *J Urol* 2020; 204:316.
- J Frankel et al. Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study. *Int J Clin Pract* 2020 December 17 (epub).
- S Varano et al. Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥65 and ≥75 Years: subpopulation analysis from the EMPOWUR randomized, international, phase III Study. *Drugs Aging* 2021; 38:137.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
 www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
 please e-mail your request to:
 permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected:  

Copyright 2021. ISSN 1523-2859

The
 Medical
 Letter